Terms: = Endocrine gland cancer AND RAD51B, ENSG00000182185, 5890, RAD51L1, O15315, hREC2, R51H2, REC2, MGC34245
32 results:
1. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
[TBL] [Abstract] [Full Text] [Related]
2. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
3. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract] [Full Text] [Related]
4. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
Hu C; Nagaraj AB; Shimelis H; Montalban G; Lee KY; Huang H; Lumby CA; Na J; Susswein LR; Roberts ME; Marshall ML; Hiraki S; LaDuca H; Chao E; Yussuf A; Pesaran T; Neuhausen SL; Haiman CA; Kraft P; Lindstrom S; Palmer JR; Teras LR; Vachon CM; Yao S; Ong I; Nathanson KL; Weitzel JN; Boddicker N; Gnanaolivu R; Polley EC; Mer G; Cui G; Karam R; Richardson ME; Domchek SM; Yadav S; Hruska KS; Dolinsky J; Weroha SJ; Hart SN; Simard J; Masson JY; Pang YP; Couch FJ
Cancer Res; 2023 Aug; 83(15):2557-2571. PubMed ID: 37253112
[TBL] [Abstract] [Full Text] [Related]
5. Optical Coherence Tomography Angiography for the Differentiation of Glaucoma from Pituitary Macroadenoma Related Optic Disc Measurements.
Zahavi A; Weinberger Y; Geffen N; Gabbay I; Mimouni M; Gal-Or O; Stiebel-Kalish H; Gaton DD
Semin Ophthalmol; 2023 Oct; 38(7):625-629. PubMed ID: 36762773
[TBL] [Abstract] [Full Text] [Related]
6. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
7. Homologous recombination-deficient mutation cluster in tumor suppressor
Prakash R; Rawal Y; Sullivan MR; Grundy MK; Bret H; Mihalevic MJ; Rein HL; Baird JM; Darrah K; Zhang F; Wang R; Traina TA; Radke MR; Kaufmann SH; Swisher EM; Guérois R; Modesti M; Sung P; Jasin M; Bernstein KA
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2202727119. PubMed ID: 36099300
[TBL] [Abstract] [Full Text] [Related]
8. rad51b Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
Xie F; Ding D; Lin C; Cunningham D; Wright M; Javed AA; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Le DT; Pishvaian M; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; McPhaul T; Burkhart RA; Burns WR; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Yu J; He J; Wolfgang CL; Zheng L; Liu D; Wu K; Laheru DA
JCO Precis Oncol; 2022 Jun; 6():e2100404. PubMed ID: 35737913
[TBL] [Abstract] [Full Text] [Related]
9. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
10. Homologous Recombination Deficiency: cancer Predispositions and Treatment Implications.
Toh M; Ngeow J
Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
[TBL] [Abstract] [Full Text] [Related]
11. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
[TBL] [Abstract] [Full Text] [Related]
12. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract] [Full Text] [Related]
13.
JuknytĖ G; LaurinaitytĖ I; VilkeviČiŪtĖ A; GedvilaitĖ G; GlebauskienĖ B; KriauČiŪnienĖ L; LiutkeviČienĖ R
In Vivo; 2021; 35(2):815-826. PubMed ID: 33622874
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition.
Cavaillé M; Uhrhammer N; Privat M; Ponelle-Chachuat F; Gay-Bellile M; Lepage M; Molnar I; Viala S; Bidet Y; Bignon YJ
Genes Chromosomes Cancer; 2021 Feb; 60(2):73-78. PubMed ID: 33099839
[TBL] [Abstract] [Full Text] [Related]
15. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian cancer after PARP Inhibition Progression.
Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
[TBL] [Abstract] [Full Text] [Related]
16. A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma.
Bradley A; Van der Meer R; McKay CJ
PLoS One; 2019; 14(9):e0222270. PubMed ID: 31498836
[TBL] [Abstract] [Full Text] [Related]
17. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract] [Full Text] [Related]
18. [The French Genetic and cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract] [Full Text] [Related]
19. The radiotherapy-sensitization effect of cantharidin: Mechanisms involving cell cycle regulation, enhanced DNA damage, and inhibited DNA damage repair.
Xu MD; Liu SL; Zheng BB; Wu J; Wu MY; Zhang Y; Gong FR; Tao M; Zhang J; Li W
Pancreatology; 2018 Oct; 18(7):822-832. PubMed ID: 30201439
[TBL] [Abstract] [Full Text] [Related]
20. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
[TBL] [Abstract] [Full Text] [Related]
[Next]
